ANZUPGO is a prescription medicine used on the skin (topical) to treat moderate to severe chronic hand eczema (CHE) in adults who are not well-controlled with or cannot use topical corticosteroids.
The use of ANZUPGO along with other JAK inhibitors or strong immunosuppressants is not recommended.
ANZUPGO is for use on the skin only. Do not use in or on your eyes, mouth, or vagina.
ANZUPGO may increase your risk of infections because it contains delgocitinib, a type of medicine called Janus kinase (JAK) inhibitors that can affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Serious infections (including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses) have happened with JAK inhibitors. Some people have been hospitalized or died.
Before using ANZUPGO: Tell your healthcare provider if you:
After starting ANZUPGO: Call your healthcare provider right away if you have signs of infection. Your provider may stop ANZUPGO until the infection is controlled.
ANZUPGO may increase the risk of certain skin cancers. Your healthcare provider will check your skin during treatment.
It is not known if ANZUPGO has the same risks as other JAK inhibitors. Increased risk of death (all causes) happened in people 50+ with at least one heart disease risk factor taking a JAK inhibitor for rheumatoid arthritis (RA) compared with TNF blockers. ANZUPGO is not for use in RA. Oral or other topical JAK inhibitors have also caused increased cholesterol. Low blood sugar in diabetics has happened after taking JAK inhibitors by mouth.
Before using ANZUPGO, tell your healthcare provider if you:
The most common side effects were application site reactions, including pain, tingling, itching, and redness; bacterial skin infections, including finger cellulitis and nail infections; and low white blood cells.
These are not all of the possible side effects of ANZUPGO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.